A. Druetta et al., EVALUATION OF 5 COMMERCIAL ANTIFUNGAL SUSCEPTIBILITY TESTING SYSTEMS, European journal of clinical microbiology & infectious diseases, 12(5), 1993, pp. 336-342
Five commercial antifungal susceptibility testing systems were studied
for repeatability and reproducibility as well as concordance of resul
ts with the MICs for ten reference strains belonging to six different
species. Repeatability was determined by testing each strain in tripli
cate on the same day, and reproducibility by repeating this triple det
ermination on three different days. On the basis of 630 yeast-antifung
al agent results for Mycototal and Mycostandard, 540 for Candifast, an
d 450 for ATB Fungus and Diff Test, repeatability was consistently equ
al to or greater than 95 %. Reproducibility was 80.07 % for Candifast
and greater than 95 % for the other systems. The concordance with the
reference MICs was 51.65 % for Candifast, 75.33 % for ATB Fungus, 80.8
9 % for Diff Test, 90.16 % for Mycostandard and 90.32 % for Mycototal.
Although the performance of Diff Test and ATB Fungus was satisfactory
, Mycototal and Mycostandard gave notably better results with imidazol
es. Mycostandard, which is easier to use and includes tests for flucon
azole and itraconazole, would seem to be potentially the most useful a
ntifungal susceptibility test available at present.